MabCure Inc. Welcomes Dr. David S. Frank As New Member of the Board of Directors

MabCure, Inc. (�MabCure�), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, welcomes Dr. David S. Frank to the company�s board of directors.

Dr. Frank has held a number of senior level executive positions at major public companies. Most recently he assumed the position of Managing Director at the privately held MEDx Associates LLC, a diagnostics and medical devices consulting company. Prior to that Dr. Frank served as Executive Director of Business Development at Ortho Clinical Diagnostics, a Johnson & Johnson company.

Dr. Frank�s industrial career began as a founding member of Kodak�s thin film diagnostics research and development team, where, over a nine-year period he was granted ten patents. As Director of Marketing and Planning Management at Kodak Clinical Diagnostics from 1982-1994, Dr. Frank served as head of point of care diagnostics; regional business manager for Asia, Africa, and Australia; and Director of Diagnostics Marketing for Japan. Dr. Frank, who earned his biochemistry PhD from Cornell University, recently served as a faculty member at the LAHAV-Tel Aviv University Graduate School of Business, where he taught at health care marketing courses for bioscience entrepreneurs.

Dr. Frank is currently the Chairman of the Board of Nehora Photonics Ltd., a medical device company located in Israel, and a board member of TogetherForever LLC.

�We are delighted to welcome David to the board,� said Dr. Amnon Gonenne, MabCure�s President and CEO. �David�s breadth of international business development and marketing experience is certain to be instrumental to the future of MabCure. With David�s leadership and expertise, we anticipate the company will accelerate toward the achievement of the shared goals of our shareholders, employees, customers, and patients alike.�

For more news and information on�MabCure Inc., please visit www.IRGnews.com/coi/MBCI where you can find a fact sheet on the company, investor presentations, and more.

About MabCure Inc.

MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company�s website www.mabcure.com.

This news release contains �forward-looking statements�. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company or the University and the inability of the Company or the University to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company or the University assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024